8-K: Poseida Therapeutics Announces Positive Clinical Data and Financial Results for 2023, Outlines 2024 Milestones

Poseida Therapeutics reported positive clinical trial data for its allogeneic CAR-T therapies and provided financial results for 2023, highlighting a strong cash position and upcoming milestones.

Summary

• Poseida Therapeutics announced its fourth quarter and full year 2023 financial results, along with updates on its clinical programs.
• The company presented positive Phase 1 data for its P-BCMA-ALLO1 therapy at ASH 2023, showing an 82% overall response rate in relapsed/refractory multiple myeloma patients.
• Poseida initiated a clinical trial for its first allogeneic dual CAR-T program, P-CD19CD20-ALLO1.
• The company plans to present allogeneic CAR-T data at AACR in April 2024, focusing on P-BCMA-ALLO1 activity in BCMA-experienced patients and lymphodepletion strategies.
• Preclinical data for P-FVIII-101 gene therapy was also presented at ASH, demonstrating stable Factor VIII expression.
• Full year 2023 revenue was $64.7 million, down from $130.5 million in 2022, primarily due to a decrease in initial license revenue from the Roche collaboration.
• Research and development expenses for the full year 2023 were $156.8 million, compared to $152.9 million in 2022.
• The company reported a net loss of $123.4 million for the full year 2023, compared to a net loss of $64.0 million in 2022.
• Poseida's cash, cash equivalents, and short-term investments totaled $212.2 million as of December 31, 2023, which is expected to fund operations into the second half of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data and a strong cash position, with some concerns about revenue decline and increased net loss. The overall tone is optimistic and forward-looking.

Positives

• The 82% overall response rate for P-BCMA-ALLO1 is very promising for patients with relapsed/refractory multiple myeloma.
• The favorable safety profile of P-BCMA-ALLO1, with low incidences of CRS and neurotoxicity, is a significant positive.
• The company's cash position of $212.2 million is strong and expected to fund operations into the second half of 2025.
• The $30 million milestone payment from Roche is a positive indicator of the collaboration's progress.
• The initiation of the P-CD19CD20-ALLO1 trial expands Poseida's pipeline of allogeneic CAR-T therapies.
• The preclinical data for P-FVIII-101 gene therapy is encouraging for the treatment of Hemophilia A.
• Poseida's proprietary non-viral technologies enable high levels of CAR-TSCM in their products.

Negatives

• Full year 2023 revenue decreased to $64.7 million from $130.5 million in 2022.
• The company reported a net loss of $123.4 million for the full year 2023, which is significantly higher than the $64.0 million loss in 2022.
• The decrease in revenue was primarily due to a reduction in initial license revenue from the Roche collaboration.

Risks

• The company relies on third parties for various aspects of its business, which could pose risks.
• There are risks and uncertainties associated with the development and regulatory approval of novel product candidates.
• Poseida has limited control over the efforts and resources that Roche devotes to advancing development programs under their collaboration agreement.
• The company may not receive all potential fees and payments under the Roche collaboration agreement.
• Roche has the ability to early terminate the collaboration, which could negatively impact Poseida.
• The company's ability to retain key scientific or management personnel is a risk.

Future Outlook

Poseida expects its current cash balance, along with remaining milestones and payments from Roche, to fund operations into the second half of 2025, with potential for further extension through additional payments or business development.

Management Comments

• Kristin Yarema, Ph.D., President and Chief Executive Officer, stated that 2024 looks to be a breakout year for Poseida, building on recent allogeneic BCMA clinical data.
• Dr. Yarema also highlighted the company's ability to achieve high levels of CAR-TSCM in their products due to their proprietary, nonviral technologies.

Industry Context

Poseida's advancements in allogeneic CAR-T therapy and gene therapy are part of a broader trend in the biotechnology industry towards developing more effective and accessible treatments for cancer and rare diseases. The company's collaboration with Roche highlights the growing interest in allogeneic cell therapies.

Comparison to Industry Standards

• Poseida's 82% ORR in relapsed/refractory multiple myeloma with P-BCMA-ALLO1 is competitive with other CAR-T therapies, including autologous approaches like Abecma and Carvykti, which have shown ORRs in the 70-90% range in similar patient populations.
• The favorable safety profile of P-BCMA-ALLO1, with low rates of severe CRS and neurotoxicity, is a key differentiator compared to some autologous CAR-T therapies that can have higher rates of these adverse events.
• The development of allogeneic CAR-T therapies like Poseida's P-BCMA-ALLO1 and P-CD19CD20-ALLO1 aims to address the limitations of autologous CAR-T therapies, such as manufacturing complexity and patient access issues, which are also being targeted by companies like Allogene Therapeutics and CRISPR Therapeutics.
• Poseida's focus on TSCM-rich CAR-T cells and non-viral gene editing technologies is a unique approach compared to other companies using viral vectors for gene delivery, such as bluebird bio and Orchard Therapeutics.
• The company's gene therapy program for Hemophilia A, P-FVIII-101, is competing with other gene therapy approaches in development by companies like BioMarin and Sangamo Therapeutics, which are also targeting stable Factor VIII expression.

Management Changes

Stakeholder Impact

• Shareholders may be positively impacted by the promising clinical data and strong cash position.
• Employees may be impacted by the management changes and the company's growth.
• Patients with cancer and rare diseases may benefit from the development of new therapies.
• The collaboration with Roche may impact suppliers and other partners.

Next Steps

• Poseida plans to present data on P-BCMA-ALLO1 at the AACR Annual Meeting on April 8, 2024.
• The company will present initial clinical findings from the Phase 1 trial of P-MUC1C-ALLO1 at AACR.
• Poseida expects to provide an interim data update on P-CD19CD20-ALLO1 in the second half of 2024.
• The company plans to advance P-PSMA-ALLO1 into IND-enabling studies in 2024.
• Poseida will host a gene therapy R&D Day on April 17, 2024.
• The company plans to host a cell therapy R&D Day in the second half of 2024.
• Poseida is developing a strategy in inflammation and autoimmune disease and will provide an update at an appropriate time.

Key Dates

Keywords

CAR-T, allogeneic, gene therapy, multiple myeloma, clinical trial, P-BCMA-ALLO1, Roche, Hemophilia A, P-FVIII-101, biotechnology, cancer, P-CD19CD20-ALLO1, P-MUC1C-ALLO1, P-PSMA-ALLO1